Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Saved in:
| Title: | Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. |
|---|---|
| Authors: | Kraft CS; Department of Pathology and Laboratory Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA, USA., Sims M; Section of Infectious Diseases and International Medicine, Department of Internal Medicine, Beaumont Royal Oak, Royal Oak, MI, USA.; Departments of Internal Medicine and Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI, USA., Silverman M; Western University, London, ON, Canada., Louie TJ; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Feuerstadt P; Division of Digestive Disease, Yale University School of Medicine, New Haven, CT, USA.; PACT-Gastroenterology Center, Hamden, CT, USA., Huang ES; Department of Gastroenterology, Palo Alto Medical Foundation, Sutter Health, Mountain View, CA, USA., Khanna S; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA., Berenson CS; University at Buffalo, VA Western New York Healthcare System, Buffalo, NY, USA., Wang EEL; Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA., Cohen SH; University of California Davis Health, Sacramento, CA, USA., Korman L; Gastroenterology and Hepatology, Chevy Chase Clinical Research, Chevy Chase, MD, USA., Lee C; Island Medical Program, University of British Columbia and University of Victoria, Vancouver, BC, Canada., Kelly CR; Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA., Odio A; Adventist Health, Simi Valley, CA, USA., Cook PP; Brody School of Medicine at East, Carolina University, Greenville, NC, USA., Lashner B; Cleveland Clinic, Cleveland, OH, USA., Ramesh M; Division of Infectious Diseases, Henry Ford Health, Detroit, MI, USA., Kumar P; Division of Infectious Diseases and Tropical Medicine, Georgetown University Medical Center, Washington, DC, USA., De A; Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA., Memisoglu A; Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA., Lombardi DA; Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA., Hasson BR; Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA. bhasson@serestherapeutics.com., McGovern BH; Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA., von Moltke L; Seres Therapeutics, 200 Sidney Street, Cambridge, MA, 02139, USA., Pardi DS; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. |
| Corporate Authors: | ECOSPOR III and ECOSPOR IV investigators |
| Source: | Infectious diseases and therapy [Infect Dis Ther] 2024 Oct; Vol. 13 (10), pp. 2209-2210. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
